Tuberculosis Therapeutics Market Introduction and Overview
According to SPER Market Research, the Global Tuberculosis Therapeutics Market is estimated to reach USD 3.77 billion by 2034 with a CAGR of 5.38%.
The report includes an in-depth analysis of the Global Tuberculosis Therapeutics Market, including market size and trends, product mix, Applications, and supplier analysis. The tuberculosis (TB) therapeutics market is driven by rising TB prevalence, increasing government and non-government initiatives, and advancements in drug development. The introduction of novel drugs, rapid diagnostic tools, and shorter treatment regimens further fuel market growth. However, significant challenges persist, including the emergence of multidrug-resistant TB (MDR-TB), high treatment costs, and limited access to medications in low-income regions. Additionally, lengthy drug approval processes and inadequate healthcare infrastructure in developing nations hinder progress. Despite these challenges, continuous research, global funding, and public-private partnerships are expected to accelerate innovation, improving treatment outcomes and expanding market opportunities in the coming years.
By Disease Type Insights: In 2024, the market for tuberculosis treatments was dominated by the active TB sector. The increasing incidence of active tuberculosis in the world's population is the reason for the segment's domination. Mycobacterium tuberculosis, which primarily affects the lungs, is the cause of this illness. Although most individuals get the disease years after infection, the chance of getting it is highest in the first year. Approximately 10% of those infected with M. tuberculosis are predicted to experience an active infection at some point in their lives. Over the course of the forecast period, the latent TB sector is anticipated to increase at the fastest rate. The segment's growth is ascribed to the prevalence of the disease among the general population, which many people are unaware of. This type of infection is typically classified as existing in the body without causing illness.
By Therapy Insights: In 2024, the segment with the biggest share was first-line therapy. First-line anti-tuberculosis medications include isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), streptomycin (SM), and ethambutol (EMB). Combining first-line medications with levofloxacin, a second-line TB medication, is advised by the World Health Organization. Isoniazid (INH) has been one of the most potent and targeted anti-tuberculosis medications since its first in 1952. M. tuberculosis has a high INH sensitivity. Over the course of the forecast period, the second-line therapy segment is anticipated to increase at the fastest rate. The rising incidence of drug-resistant tuberculosis in the population is the reason for the segment's expansion.
By Route of Administration Insights: In 2024, the oral category had the biggest share. Three oral drugs are used to treat TB: pyrazinamide, isoniazid, and rifampin. They can be taken either alone or in conjunction with one or more other anti-TB drugs. Rifampin, a medication in the antibiotic medicine class, inhibits or stops bacterial development. For the first two months, isoniazid, pyrazinamide, rifampicin, and ethambutol are administered daily simultaneously; after that, just isoniazid and rifampicin are administered for the next four months.
By Regional Insights: In terms of market share, the MEA region dominated in 2024 and is anticipated to continue to do so for the duration of the forecast. This is explained by the rising incidence of tuberculosis in the area. TB is the tenth most common cause of death worldwide, killing 1.6 million individuals, with over 25% of those fatalities typically taking place in Africa. Furthermore, a significant health danger in the fight against tuberculosis is the occurrence of multidrug-resistant TB.
Market Competitive Landscape:
Cipla Limited, GlaxoSmithKline, Johnson & Johnson, Lupin Limited, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd.
Recent Developments:
- In 2022, A significant advancement is the World Health Organization's endorsement of a novel all-oral six-month regimen combining pretomanid, bedaquiline, moxifloxacin, and linezolid (BPaLM) for treating MDR/RR-TB.
- In 2024, As of August 2024, there are 29 drugs in Phase I, II, or III clinical trials for TB treatment, up from 28 in 2023 and eight in 2015. This increase reflects accelerated drug development efforts.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Disease Type, By Therapy, By Route of Administration. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | Cipla Limited, GlaxoSmithKline, Johnson & Johnson, Lupin Limited, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd. and others. |
Key Topics Covered in the Report:
- Global Tuberculosis Therapeutics Market Size (FY’2021-FY’2034)
- Overview of Global Tuberculosis Therapeutics Market
- Segmentation of Global Tuberculosis Therapeutics Market By Disease Type (Active TB, Latent TB)
- Segmentation of Global Tuberculosis Therapeutics Market By Therapy (First-Line Therapy, Second-Line Therapy)
- Segmentation of Global Tuberculosis Therapeutics Market By Route of Administration (Oral, Parenteral, Others)
- Statistical Snap of Global Tuberculosis Therapeutics Market
- Expansion Analysis of Global Tuberculosis Therapeutics Market
- Problems and Obstacles in Global Tuberculosis Therapeutics Market
- Competitive Landscape in the Global Tuberculosis Therapeutics Market
- Details on Current Investment in Global Tuberculosis Therapeutics Market
- Competitive Analysis of Global Tuberculosis Therapeutics Market
- Prominent Players in the Global Tuberculosis Therapeutics Market
- SWOT Analysis of Global Tuberculosis Therapeutics Market
- Global Tuberculosis Therapeutics Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Tuberculosis Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Tuberculosis Therapeutics Market
7. Global Tuberculosis Therapeutics Market, By Disease Type (USD Million) 2021-2034
7.1. Active TB
7.2. Latent TB
8. Global Tuberculosis Therapeutics Market, By Therapy (USD Million) 2021-2034
8.1. First-Line Therapy
8.2. Second-Line Therapy
9. Global Tuberculosis Therapeutics Market, By Route of Administration (USD Million) 2021-2034
9.1. Oral
9.2. Parenteral
9.3. Others
10. Global Tuberculosis Therapeutics Market, (USD Million) 2021-2034
10.1. Global Tuberculosis Therapeutics Market Size and Market Share
11. Global Tuberculosis Therapeutics Market, By Region, (USD Million) 2021-2034
11.1. Asia-Pacific
11.1.1. Australia
11.1.2. China
11.1.3. India
11.1.4. Japan
11.1.5. South Korea
11.1.6. Rest of Asia-Pacific
11.2. Europe
11.2.1. France
11.2.2. Germany
11.2.3. Italy
11.2.4. Spain
11.2.5. United Kingdom
11.2.6. Rest of Europe
11.3. Middle East and Africa
11.3.1. Kingdom of Saudi Arabia
11.3.2. United Arab Emirates
11.3.3. Qatar
11.3.4. South Africa
11.3.5. Egypt
11.3.6. Morocco
11.3.7. Nigeria
11.3.8. Rest of Middle-East and Africa
11.4. North America
11.4.1. Canada
11.4.2. Mexico
11.4.3. United States
11.5. Latin America
11.5.1. Argentina
11.5.2. Brazil
11.5.3. Rest of Latin America
12. Company Profile
12.1. Cipla Limited
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. GlaxoSmithKline
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Johnson & Johnson
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. Lupin Limited
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. Merck & Co., Inc.
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Novartis AG
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. Pfizer Inc.
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Sanofi
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Sun Pharmaceutical Industries Ltd.
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links